Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ibritumomab Tiuxetan
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)
Details : Zevalin (Ibritumomab Tiuxetan) is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lymphoma, Follicular.
Product Name : Zevalin
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
August 10, 2012
Lead Product(s) : Ibritumomab Tiuxetan
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ibritumomab Tiuxetan
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Biogen
Deal Size : Inapplicable
Deal Type : Inapplicable
Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma
Details : Ibritumomab Tiuxetan is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Lymphoma.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
February 24, 2012
Lead Product(s) : Ibritumomab Tiuxetan
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Biogen
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ibritumomab Tiuxetan
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zevalin (Ibritumomab Tiuxetan) is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lymphoma, Large B-Cell, Diffuse.
Product Name : Zevalin
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
January 13, 2012
Lead Product(s) : Ibritumomab Tiuxetan
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable